The 10th World Orphan Drug Congress is taking place 12th–14th November, 2019 in Barcelona, Spain; and is not an event to be missed.
Now recognized as the largest and most established European orphan drug event, we are once again proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape. The 12th annual event will address the strategic and commercial aspects of bringing new treatments to patients who suffer from rare diseases.
For 2019 we will be expanding the meeting further with a dedicated co-conference on Cell & Gene Therapy and even more dedicated content and tracks than ever before on Clinical/Product Development, Market Access & Pricing, Manufacture, Science & Strategy, Pitch & Partner and Precision Medicine. We will also continue the highly popular Pre-Congress Workshops.
Download Full agenda here
Book your ticket here
Andrzej Rys, Director, Health Systems, Medical Products and Innovation, DG SANTE
Kristina Larsson, Head of Orphan Drugs, EMA
Bernard J. Grimm, Director, Healthcare Biotechnology, Europabio
Delphine Roulland, Senior Manager Public Affairs, EUCOPE
Ulrika Vestin, Swedish Association of Local Authorities and Regions (SKL),
Prof Maurizio Scarpa, Coordinator, European Reference Network for Hereditary Metabolic Diseases (MetabERN)
Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health
Dr Vinciane Pirard, Co-Chair of Rare Disease & OMP Joint Task Force EFPIA-Europabio & Senior Director Public Affairs, Sanofi
Mark Rothera, Chief Executive Officer, Orchard Therapeutics
Stuart Peltz, Chief Executive Officer, PTC Therapeutics
Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer
Sander van Deventer, Chief Scientific Officer, UniQure
Frederic Chereau, Chief Executive Officer, LogicBio Therapeutics
Marcus Guardian, Chief Operating Officer, EUnetHTA